Stifel Downgrades Fate Therapeutics (FATE ) to Hold
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $2.57 +1.98%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Stifel analyst Benjamin Burnett downgraded Fate Therapeutics (NASDAQ: FATE ) from Buy to Hold with a price target of $5.30 (from $107.00).
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $11.00 yesterday.
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- Petronet LNG Ltd. (PLNG:IN) PT Raised to INR310 at ICICI Securities
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
